1. Risk of schizophrenia in patients with polycystic ovary syndrome: a nationwide population-based cohort study from Taiwan.
- Author
-
Chen, Shih-Fen, Yang, Yu-Cih, Hsu, Chung-Y, and Shen, Yu-Chih
- Subjects
- *
POLYCYSTIC ovary syndrome , *22Q11 deletion syndrome , *PEOPLE with schizophrenia , *COHORT analysis , *DIAGNOSIS , *REGRESSION analysis , *RESEARCH , *SCHIZOPHRENIA , *EVALUATION research , *COMPARATIVE studies , *METFORMIN , *LONGITUDINAL method , *DISEASE complications - Abstract
Objectives: To investigate whether patients with polycystic ovary syndrome (PCOS) are at increased risk for incident schizophrenia and whether PCOS treatment (clomiphene, cyproterone, or metformin) affects the incidence of schizophrenia.Methods: An overall of 7146 PCOS patients and 28,580 non-PCOS controls matched by age, index year, and Charlson Comorbidity Index (CCI) score were included between 2000 and 2012 and followed up until 2013 using a validated nationally representative sample from Taiwan. Participants newly diagnosed as schizophrenia were defined as incidents. Cox regression analysis was used to calculate the hazard ratio (HR) with a 95% confidence interval (CI) of the schizophrenia incidence rate between the two studied groups.Results: PCOS patients were at increased risk of incident schizophrenia compared to non-PCOS controls after adjusting for age, CCI score, comorbidities, and different treatment options (0.49 versus 0.09 per 1000 person-years, HR: 6.93, 95% CI: 3.25-14.7). After adjusting for above-mentioned covariates, metformin treatment had a protective effect against the incident schizophrenia compared to non-users (HR: 0.16, 95% CI: 0.06-0.41). Also, treatment with clomiphene and cyproterone had only a limited impact on the incident schizophrenia.Conclusion: This study shows PCOS patients are at increased risk of incident schizophrenia, and the metformin treatment has a protective effect against incident schizophrenia. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF